We gebruiken cookies om ervoor te zorgen dat onze site zo soepel mogelijk draait. Als je doorgaat met het gebruiken van deze site, gaan we er vanuit dat je ermee instemt.
The table below is a review of notable updates that occurred in April 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
BioVersys AG, a multi─asset, clinical stage biopharmaceutical company focusing on R&D of novel antibacterial products for serious life─threatening infections caused by multi─drug resistant (MDR) bacteria, announced the
Transient receptor potential canonical 3 (TRPC3) protein belongs to the TRP family of nonselective cation channels. Its activation occurs by signaling through a G protein-coupled receptor (GPCR) and a...
The Food and Drug Administration (FDA) has granted Fast Track designation to ECUR-506 for the treatment of neonatal onset ornithine transcarbamylase deficiency.
4 uur geleden
4 min
Video
